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Dear Editor,
H
epatitis C virus (HCV) has been recognized 
as a major health problem worldwide. The 
estimated number of infected individuals is over 170 
million people worldwide (1). After hepatitis B, it is the 
most important cause of chronic hepatitis, cirrhosis 
and hepatocellular carcinoma. Therefore, prevention 
of  HCV  infection  is  one  of  the  most  important 
public  health  concerns,  because  the  majority  of 
infected people would experience chronic hepatitis 
(2, 3). HCV can be easily transmitted through blood 
products  transfusion  and  infected  syringes.  No 
surprise, the infection rate is remarkably high among 
injecting drug abusers (IDUs) (4, 5).
HCV has been identified as the most common viral 
infection affecting IDUs (6). Sharing contaminated 
needles  and  syringes,  going  to  shooting  galleries, 
using cocaine, unprotected sex, and sharing shaving 
equipments,  are  all  among  the  major  causes  of 
contaminating  IDUs  with  HCV  (7,  8).  In  some 
countries  such  as  India,  Pakistan,  Indonesia,  and 
Thailand,  the  prevalence  of  anti-HCV  antibody 
among the IDUs is reported to be at least 90% (9). 
The  reported  prevalence  from  Iran  ranged  from 
38% to 47% (10) and in another study it is about 60% 
(11).
“Norjizac,” also known as “hand-made Temgizac,” 
and “Ab Crack (Crack solution),” is a slang name for 
a drug which is abused by a number of IDUs in Iran 
since five years ego. It is usually used as intravenous 
injections,  although  some  of  drug  abusers  use 
Norjizac  intramuscularly  and/or  subcutaneously. 
Norjizac is one of the most hard drugs in Iran and 
accompanying  several  complications  like  abscess 
formation, development of septic emboli and soft 
tissue infections in IDUs. 
Based  on  reports  on  probable  human 
contamination in Norjizac vials, we conducted this 
study to find out why some of IDUs who used the 
drug  have  developed  HCV  infection  without  any 
history of sharing in injection tools.
  In a case series reported from Isfahan conducted 
in 2008, 14 vials of Norjizac bought from smugglers 
from  various  locations  within  four  months,  were 
tested  for  HCV.  Two-hundred  micro-liters  from 
the solution in each vial were obtained and using a 
high pure viral nucleic acid kit (Roche Diagnostics 
GmbH,  Germany),  RNA  extraction  was  done. 
Thereafter, using Moloney Murine Leukemia Virus 
(M-MuLV)  reverse  transcriptase  (Fermentas,  Life 
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Science),  C-DNA  was  produced.  Using  specific 
primers  and  a  probe  for  the  detection  of  HCV 
(Tagman probe), PCR was done (Corrbette Research 
6000). All laboratory staff was unaware of the nature 
of the drug under analysis. Overall, two (14%; 95% 
confidence interval [CI]: 0%–32%) of the 14 tested 
vials were found positive for HCV with a viral load 
>104/mL.
  We found that Norjizak, itself, can be contaminated 
with  HCV  and  that  avoiding  shared  needles  and 
syringes is not enough for being infected by HCV 
in Norjizak abusers. The same thing may be true for 
other countries that manufacture this drug.
Although  conduction  of  “harm  reduction 
programs,”  has  resulted  in  significant  decrease  in 
preventing HIV infection among IDUs, the prevalence 
and incidence of hepatitis C still remains high among 
this group (12-14). One of the most important points 
about the survival of HCV is its prolonged stay in 
the environment. For instance, HCV RNA has been 
found to be stable in plasma or serum at 40 ºC for 
seven days (15). It is believed that HCV can live outside 
the body for a long time—estimates vary from 7–10 
days to weeks or months (16). 
  Hepatitis C is common among IDUs and needs 
longterm and expensive treatment courses. In Iran, 
establishment of the “harm reduction program” has 
been accepted by the higher governmental authorities 
and we adapted it to our religious and traditional 
culture. Harm reduction can work effectively only if 
it is genuinely supported by an enabling policy and 
legislative  environment  (17).  Formerly,  we  thought 
that HCV was transmitted only through needle and 
syringe sharing among the IDUs, but in this study, 
we found that a new and potentially very dangerous 
route of viral spread exists. 
  In Conclusion, in order to decrease HCV infection 
in IDUs, it is strongly recommended to follow up 
drug contamination (especially Norjizac) and develop 
community awareness about it. 
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